Problems with FDA's regulation of the antiarrhythmic drugs Tambocor and Enkaid  hearing before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, House of Representatives, One Hundred Second Congress, first session, April 10, 1991. 

 - Washington  U.S. G.P.O.  For sale by the U.S. G.P.O., Supt. of Docs., Congressional Sales Office  1992. 
 - iii, 327 p.  ill.  24 cm. 
<br/><br/> Distributed to some depository libraries in microfiche.  Shipping list no.: 92-111-P. 
<br/><br/>Includes bibliographical references. 
<br/><br/><label>ISBN: </label>0160372275 
<br/><br/><label>Subjects--Corporate Names: </label><br/>United States Food and Drug Administration. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cardiovascular agents.--United States.<br/>Legislation, Drug--United States.<br/>Anti-Arrhythmia Agents--standards<br/>Anti-Arrhythmia Agents--adverse effects<br/>Drugs--Administration--Government policy--United States.<br/>Arrhythmia--Treatment--United States.
<br/><br/><label>GPO Item No.: </label>1016-A, 1016-B (MF) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.G 74/7:An 8/7